Apyx Medical Corp: Form 10-Q for the period ended Mar 31, 2020
Filed with the SEC on May 11, 2020 and accepted by EDGAR at May 11, 2020, 08:43 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-01-01 to 2020-03-31 | $5.0m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-01-01 to 2020-03-31 | $2.0m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-01-01 to 2020-03-31 | $3.0m | us-gaap:GrossProfit |
| Research and development | 3 months2020-01-01 to 2020-03-31 | $980.0k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-01-01 to 2020-03-31 | $3.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-01-01 to 2020-03-31 | −$7.5m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-01-01 to 2020-03-31 | $6.0k | us-gaap:InterestExpense |
| Income tax | 3 months2020-01-01 to 2020-03-31 | −$4.9m | us-gaap:IncomeTaxExpenseBenefit |
| Operating cash flow | 3 months2020-01-01 to 2020-03-31 | −$7.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2020-01-01 to 2020-03-31 | $90.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-03-31 | $51.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-03-31 | $74.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-03-31 | $82.1m | us-gaap:Assets |
| Current liabilities | At period end2020-03-31 | $10.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-03-31 | $11.7m | us-gaap:Liabilities |
| Shareholders' equity | At period end2020-03-31 | $70.4m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000719135-20-000043. Last ingested by Listed: Nov 5, 2026, 13:09 ET. Listed shows no prices and gives no investment advice.